This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (32)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Leo E. Hollister, MD; Philip Berger, MD; Floradell L. Ogle, RN; Roger C. Arnold, MD; August Johnson, PhD

Arch Gen Psychiatry. 1974;31(4):468-470.

Abstract
Protirelin (formally known as thyrotrophin releasing hormone [TRH]) was evaluated as a treatment in depression in two independent investigations using a similar protocol. The latter was designed so that some patients received three 600µg intravenous injections of protirelin early in their course and others received them toward the end of their course of treatment. Regardless of when protirelin was given in the course of depression, or how the course of the illness was measured, it seemed to be devoid both of therapeutic and of major adverse effects.

Author Affiliations
From the Veterans Administration Hospital, Palo Alto, Calif (Drs. Hollister and Berger and Ms. Ogle); and the Veterans Administration Hospital, Danville, Ill (Drs. Arnold and Johnson).

Footnotes
Accepted for publication June 10, 1974.

Reprint requests to 3801 Miranda Ave, Palo Alto, CA 94304 (Dr. Hollister).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Thyrotropin-releasing hormone: stimulation of colonic activity following intracerebroventricular administration
Smith et al.
Science 1977;196:660-662.
ABSTRACT  

Pituitary Response to Thyrotropin-Releasing Hormone in Depression
Hollister et al.
Arch Gen Psychiatry 1976;33:1393-1396.
ABSTRACT